Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
My Portfolio
Rigel Pharmaceuticals
(NQ:
RIGL
)
3.745
USD
-0.035 (-0.93%)
Official Closing Price
Updated: 7:30 PM EST, Jan 21, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,190,600
Open
3.780
Bid (Size)
3.710 (2)
Ask (Size)
3.800 (1)
Prev. Close
3.780
Today's Range
3.650 - 3.830
52wk Range
1.230 - 5.240
Shares Outstanding
163,580,297
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Rigel Pharmaceuticals Provides Business Update
January 11, 2021
TAVALISSE® preliminary 2020 net product sales of approximately $61.7 million, a year-over-year increase of 41%
From
PR Newswire
Rigel to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 07, 2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 39th Annual J.P....
From
PR Newswire
Performance
YTD
+7.93%
+7.93%
1 Month
+0.94%
+0.94%
3 Month
+49.80%
+49.80%
6 Month
+41.32%
+41.32%
1 Year
+37.68%
+37.68%
More News
Read More
Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023
December 17, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023
December 17, 2020
From
PR Newswire
Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition
December 04, 2020
From
PR Newswire
Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
November 23, 2020
From
PR Newswire
Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia
November 17, 2020
From
PR Newswire
5 Penny Stocks On Robinhood To Buy Under $3; 1 With A 173% Target
November 23, 2020
From
Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Rigel to Present at the Jefferies Virtual London Healthcare Conference
November 10, 2020
From
PR Newswire
XBI's Holdings Could Mean 41% Gain Potential
January 07, 2021
Tags
ETFs
From
ETF Channel
Notable Wednesday Option Activity: RIGL, UNFI, ISEE
December 16, 2020
Tags
Stocks
From
Market News Video
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.